My 2nd Semister Presentation

1. 1
Presented By:-
Mr. Bhosale Pramod M.
M.Pharm (sem-2nd)
Dept. of Pharmaceutics
Roll No-02
Guided by:-
Prof. Ambekar A. W
M. Pharm.
Dept. of Pharmaceutics
DR.VITTHALRAO VIKHE PATIL FOUNDATION’S
COLLEGE OF PHARMACY, AHMEDNAGAR.
A Seminar on
MICROEMULSION

2. CONTENT
1. Objectives
2. Introduction
3. Advantages
4. Types
5. Method of Preparation
6. Characterization
7. Application
8. Rescent advancement
9. Marketed Formulation
10. References
2

3. OBJECTIVES
1) Improved drug solubilization capacity
2) Long shelf life
3) Easy of preparation
4) Improvement of bio-availability
3

4. INTRODUCTION
 Microemulsion is defined as Isotropic mixtures of natural or synthetic oils, Water,
surfactants and Cosurfactant”.
 Micro emulsions are clear, transparent, thermodynamically stable dispersions of oil
and water, stabilized by an interfacial film of surfactant frequently in combination
with a co-surfactant.
 The Diameter is Generally Less than 100nm.
 Microemulsion have been used to improve the solubility, chemical stability, and
oral bioavailability of many poorly water soluble drugs.
ALTERNATIVE NAMES:-
 Transparent emulsion
 Swollen micelle
 Micellar solution
 Solubilized oil
4

5. Emulsion Microemulsion
I- Microemulsion II- Emulsion 5

6. CONTENTS OF MICROEMULSION
1) Oil phase :-
Ex.- Olive oil & Captex 355
2) Surfactants :-
Ex.- Tween 80 & Span 80
3) Cosurfactant/Stabilizer :-
Ex.- Propylene glycol & PEG 600
4) Water
6

7. Advantages:-
 Low pain sensation at injected site.
 Easy of manufacturing .
 Thermodynamically stable system.
 Helpful in taste masking.
 Provides protection from hydrolysis and oxidation as drug in oil
phase in O/W microemulsion is not exposed to attack by water and
air.
 Require minimum energy for formation.
 Microemulsion have low viscosity compared to other emulsion
7

8. TYPES
O/W Microemulsion
W/O Microemulsion
Bi continuous Microemulsion
8

9. METHODES OF PREPARATION
1) Phase Inversion Method:-
Temperature range in which an o/w microemulsions inverts to a w/o type.
 Using non-surfactants:- polyoxyethylene are very suspectible to
temperature.
with increasing the temperature, the polyoxyethylene group becomes
dehydrated, altering critical packing parameter which results in the
phase inversion.
 For ionic surfactants:- increasing temperature, increase the electrostatic
repulsion between the surfactant headgroups thus causing reversal of
film carvature.
Hence, the effect of temperature is opposite to the effect seen with non-ionic
surfactants.
9

10. 2. Phase titration method:-
Oil + Surfactant + Cosurfactant
Clear dispersion
Microemulsion
Vortex mixing / Stirring
Titration with water
Vortex mixing / Stirring
10

11. CHARACTERIZATION
Characterization
Phase
Behaviour
Studies
Scattering
Technique
Nuclear
Magnetic
Resonance
Studies
Electron
Microscopic
studies
Interfacial
Tension,
Electric
Conductivity
Viscosity
Measurement
11

12. APPLICATIONS
 Oral bioavailability enhancement poorly water soluble
drugs
 Protection against Biodegradation
 Ocular Drug delivery System
 Parenteral Drug Delivery System
 Topical Drug Delivery System
 Mucosal Drug Delivery System
 Transdermal Drug Delivery System
 Pulmonary Drug delivery system
 For Solubilization
 In Biotechnology
 In Cosmetics
 In Nasal Formulations
 In Detergency
12

13. RESCENT ADVANCEMENT
Drug Name Route Purpose/Result
Apormorphine HCl Transdermal Increased the
permeability
Ketoprofen Transdermal Enhancement of
permeability
Estradiol Transdermal Improvement in
solubilization
Aceclofenac Dermatological Increased the solubility
Diclofenac Transdermal Permeability
enhancement
Dexamethasone Topical Ocular Enhanced the
Bioavailability
Chloramphenicol Ocular Increased the solubility
13

14. Marketed Preparations
Brand Drug Dosage form Dose(mg) Indication
Neoral® Cyclosporine Soft gelatin capsules 25, 100 Immunosuppressant
Norvir® Ritonavir Soft gelatin capsules 100 HIV antiviral
Lipire® Fenofibrate Hard gelatin capsules 200 Antihypertensive
Convule® Valproic acid Soft gelatin capsules 100, 200 Antiepileptic
14

15. REFERENCES
1. Patel PA, Chaulang GM, Akolkotkar A, Mutha SS, Handicap SR and Bhosale AV. “Self
Emulsifying Drug Delivery System: A Review” Research J. Pharm. And Tech. 2008; 1(4):
313-323.
2. T. Gershanik and S. Benita, "Positively-charged self-emulsifying oil formulation for
improving oral bioavailability of progesterone," Pharm. Dev. Technol. 1, 147–157 (1996).
3. Transdermal Drug Delivery Development Issue & Research Initiatives. Edited by
Handgraft J.,Gay R. Vol-35. 1-17.
4. Ansel H., Popovich N. Allen L., Pharmaceutical Dosage forms and Delivery System, 7th
Edition. Malvern. USA: William & Wilkins. 298-313.
5. Microemulsion-based media as novel drug delivery systems www.Elsevier.Com/ locate /
drugdeliv advanced drug delivery reviews 45 (2000) 89–121
6. www.slideshare.com
7. www.authorstream.com
15

16. 16